Company Profile

GW Pharmaceuticals Ltd is a United Kingdom-based company that operates as a biopharmaceutical company. The Company manufactures pharmaceutical products. The Company specializes in developing, processing, and manufacturing drugs in pharmaceutical preparations for human and veterinary uses. The Company serves customers worldwide.

Employees

1,161

Sector

Biotechnology & Medical Research

More about the company

13/21/13	Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav	RE
10/21/10	Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures	MT
10/21/10	Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug	MT
10/21/10	Gw Pharmaceuticals Receives Approval for Epidyolex (Cannabidiol) from the MHRA for the Treatment of Seizures Associated with Tuberous Sclerosis Complex	CI
17/21/17	Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy	MT
17/21/17	Jazz Pharmaceuticals : Updates FY2021 Outlook to Reflect GW Pharmaceuticals Purchase	MT
26/21/26	Palla Pharma : Names New CEO; Shares Soar 18%	MT
10/21/10	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index	CI
05/21/05	Jazz Pharmaceuticals : Completes Purchase of GW Pharmaceuticals	MT
05/21/05	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Composite Index	CI
05/21/05	Jazz Pharmaceuticals plc completed the acquisition of GW Pharmaceuticals plc.	CI
04/21/04	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Biotechnology Index	CI
03/21/03	Gw Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2021	CI

04/21/04	GW Pharmaceuticals : SVB Leerink Downgrades GW Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $220 from $200	MT
04/21/04	GW Pharmaceuticals : Morgan Stanley Downgrades GW Pharmaceuticals to Equal-Weight From Overweight, Adjusts Price Target to $220 From $193	MT
04/21/04	GW Pharmaceuticals : HC Wainwright Downgrades GW Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $220 From $162	MT
03/21/03	GW Pharmaceuticals : Needham Downgrades GW Pharmaceuticals to Hold from Buy	MT
29/20/29	GW Pharmaceuticals : Cantor Fitzgerald Adjusts Price Target on GW Pharmaceuticals to $147 From $165, Maintains Overweight Rating	MT

06/23/06	Fitch Affirms Jazz's IDR at 'BB-'; Outlook Positive	AQ
23/23/23	Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor	AQ
28/22/28	Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing	AQ
02/22/02	JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS	AQ
12/21/12	Alkame : PAO Group, Inc.'s CBD Nutraceuticals Expected To Deliver Revenue-Generating Catalyst in 2021; New Partnerships Expand Its Long-Term CBD Pharmaceutical Programs	AQ

06/21/06	HINTERGRUND/Bei Pharma-Übernahmen schlagen inzwischen oft Midcaps zu
04/21/04	Planète Bourse : La revue de presse du jeudi 4 févier 2021
04/21/04	EN DIRECT DES MARCHES : Dassault Systèmes, Carrefour, Stellantis, Air France-KLM, Daimler, PayPal, Roche, Nokia...
04/21/04	Des marchés en pause sous un déluge de résultats
04/21/04	MÄRKTE USA/Erholung verliert an Fahrt - Alphabet-Aktie mit Rekordhoch

Director	Title	Age	Since
David Spackman BRD	Director/Board Member	50	13/01/2023
Amanda Flanagan BRD	Director/Board Member	55	10/02/2025

GW PHARMACEUTICALS Share Price OTC Markets

Stocks

GWPRF

GB0030544687

Biotechnology & Medical Research

Latest news: GW PHARMACEUTICALS

Analysts' recommendations: GW PHARMACEUTICALS

Press Releases: GW PHARMACEUTICALS

News in other languages: GW PHARMACEUTICALS

Quotes and Performance

Managers and Directors: GW PHARMACEUTICALS

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GW PHARMACEUTICALS	+16.92%	+17.65%	-	-	690.7Cr
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+62.02%	6.67TCr
ARGENX SE	+0.02%	+1.07%	+11.72%	+74.73%	5.69TCr
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+98.39%	5.65TCr
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+103.27%	4.65TCr
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+36.08%	4.48TCr
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+807.84%	4.16TCr
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+53.61%	3.53TCr
GENMAB A/S	-2.97%	-9.84%	+90.91%	+61.94%	3.33TCr
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+381.71%	2.51TCr
Average	+2.71%	+2.65%	+49.18%	+186.62%	4.52TCr
Weighted average by Cap.	+0.92%	+3.07%	+49.90%	+165.96%